TIM
MYGN icon

Thompson Investment Management’s Myriad Genetics MYGN Stock Holding History

Thompson Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-7,625
Closed -$260K – 167
2014
Q4 		$260K Sell
7,625
-15
-0.2% -$532 0.05% 150
2014
Q3 		$302K Buy
7,640
+15
+0.2% +$560 0.06% 144
2014
Q2 		$297K Sell
7,625
-4,300
-36% -$160K 0.06% 145
2014
Q1 		$408K Buy
11,925
+100
+0.8% +$3.1K 0.08% 122
2013
Q4 		$248K Buy
+11,825
New +$299K 0.05% 153

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Thompson Investment Management's MYGN Position: Q1 2015 in Review

Thompson Investment Management sold out of Myriad Genetics (MYGN) in Q1 2015, closing a stake of 7,625 shares — an estimated $260K sold.

Thompson Investment Management first reported a position in MYGN in Q4 2013 and held it in 5 quarters. The position peaked at $408K in Q1 2014. 251 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

  • Thompson Investment Management reported no remaining Myriad Genetics position as of Q1 2015 after selling out during the quarter.
  • Thompson Investment Management sold 7,625 Myriad Genetics shares in Q1 2015, an estimated $260K.
  • Thompson Investment Management first reported a position in Myriad Genetics in Q4 2013 and held it in 5 quarters.
  • Thompson Investment Management's Myriad Genetics position peaked at $408K in Q1 2014.
  • 251 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on Thompson Investment Management's 13F filing for Q1 2015, filed 4 May 2015.